仙琚制药：取得倍他米松磷酸钠注射液境内生产药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Betamethasone Sodium Phosphate Injection, which is expected to enhance its product line and competitiveness [1] Group 1: Product Approval - The approved drug is Betamethasone Sodium Phosphate Injection, with a specification of 1ml: 4mg (calculated as C₂₂H₂₉FO₅) [1] - The registration classification of the drug is categorized as Class 3 chemical drugs [1] Group 2: Market Impact - The drug is primarily used for the treatment of diseases related to glucocorticoids, and the original drug has been marketed in multiple countries [1] - The approval is seen as beneficial for the company in terms of expanding its product offerings and improving its competitive position in the market [1] Group 3: Uncertainties - The research, production, and sales of the drug are subject to uncertainties influenced by policies and market factors [1]